Advances in Therapeutic Antibody Engineering
A Special Issue of International Journal of Molecular Sciences (ISSN 1422-0067) belonging to the section "Molecular Immunology".
Deadline for manuscript submissions: 30 April 2027 | Viewed by 625
Editor
2. Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
Interests: immunology; protein engineering; gene therapy
Special Issue Information
Dear Colleagues,
The landscape of therapeutic antibodies is undergoing a profound transformation. Evolving beyond traditional monospecific formats, the current wave of innovation is driven by complex, multifunctional molecules designed to unlock novel mechanisms of action and overcome clinical resistance.
This Special Issue focuses on the rapid ascent of next-generation antibody therapeutics. We highlight breakthroughs in bispecific and multispecific antibodies, the resurgence of antibody-drug conjugates (ADCs) featuring novel payloads and smarter linkers, and the unique advantages of nanobodies for challenging targets. Furthermore, we emphasize the transformative impact of artificial intelligence (AI) and machine learning in accelerating de novo antibody design and predictive developability.
We invite researchers to submit original articles and reviews covering antibody design, optimization, and clinical applications. Join us in showcasing the cutting-edge engineering strategies that are redefining precision medicine across oncology, autoimmune disorders, and beyond.
Prof. Dr. Chatchai Tayapiwatana
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- therapeutic antibodies
- bispecific antibodies
- antibody-drug conjugates (ADCs)
- nanobodies
- AI-driven drug design
- Fc engineering
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
